The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Evaluate the safety and efficacy of Pyrotinib in the transition from low-dose to normal-dose regimen for HER2-positive advanced first-line breast cancer

Trial Details

NCT ID
NCT06254690
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Pyrotinib dose escalation
  • Pyrotinib dose normal
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • The subjects voluntarily joins the study and signs the informed consent;
  • Subject is an adult female ≥ 18 years old and ≤ 70 years old at the time of informed consent.
  • HER2-positive advanced breast cancer confirmed by pathology (HER2-positive expression refers to those with at least one tumor cell immunohistochemi…
  • Stage IV breast cancer according to American Joint Committee on Cancer(AJCC) staging system version 8.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →